Healius (ASX:HLS) - Prezzo delle azioni, notizie e analisi

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

HLS Panoramica delle azioni

Healius Limited fornisce servizi diagnostici specialistici a consumatori e professionisti in Australia.

HLS analisi fondamentale
Punteggio fiocco di neve
Valutazione	5/6
Crescita futura	3/6
Prestazioni passate	0/6
Salute finanziaria	3/6
Dividendi	0/6

Premi

Negoziato a 45.3% al di sotto della nostra stima del suo valore equo

Si prevede che gli utili cresceranno del 91.09% all'anno

Negoziato a un buon valore rispetto ai pari e al settore

Analisi del rischio

Gli azionisti sono stati diluiti nell'ultimo anno

Healius Limited Concorrenti

Australian Clinical Labs

ASX:ACL

AU$730.2m

Integral Diagnostics

ASX:IDX

AU$722.8m

Capitol Health

ASX:CAJ

AU$415.6m

Sonic Healthcare

ASX:SHL

AU$13.0b

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Healius
Prezzi storici delle azioni
Prezzo attuale dell'azione	AU$1.72
Massimo di 52 settimane	AU$2.25
Minimo di 52 settimane	AU$1.08
Beta	0.73
1Variazione di 1 mese	6.83%
Variazione a 3 mesi	16.61%
Variazione di 1 anno	-21.46%
3Variazione a 3 anni	-65.18%
Variazione a 5 anni	-45.22%
Variazione dall'IPO	22.86%

Notizie e aggiornamenti recenti

Recent updates

Rendimenti per gli azionisti

	HLS	AU Healthcare	AU Mercato
7D	-0.6%	-0.4%	0.6%
1Y	-21.5%	1.8%	19.9%

Ritorno vs Industria: HLS ha avuto una performance inferiore rispetto al Australian Healthcare che ha registrato un rendimento -12.6 % nell'ultimo anno.

Rendimento vs Mercato: HLS ha avuto una performance inferiore al mercato Australian che ha registrato un rendimento 11.2 % nell'ultimo anno.

Volatilità dei prezzi

Is HLS's price volatile compared to industry and market?
HLS volatility
HLS Average Weekly Movement	6.2%
Healthcare Industry Average Movement	5.0%
Market Average Movement	8.8%
10% most volatile stocks in AU Market	17.7%
10% least volatile stocks in AU Market	3.6%

Prezzo delle azioni stabile: HLS non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale ( 5% ) di HLS è rimasta stabile nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
1994	6,994	Paul Anderson	www.healius.com.au

Healius Limited fornisce servizi diagnostici specialistici a consumatori e professionisti in Australia. L'azienda opera attraverso tre segmenti: Patologia, Imaging e Altri. Offre servizi di diagnostica per immagini, laboratori medici privati e servizi di patologia.

Healius Limited Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Healius con la sua capitalizzazione di mercato?
HLS statistiche fondamentali
Capitalizzazione di mercato	AU$1.25b
Guadagni(TTM)	-AU$636.00m
Ricavi(TTM)	AU$1.75b

0.7x

Rapporto P/S

-2.0x

Rapporto P/E

HLS è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
HLS Conto economico (TTM)
Ricavi	AU$1.75b
Costo del fatturato	AU$1.21b
Profitto lordo	AU$541.20m
Altre spese	AU$1.18b
Guadagni	-AU$636.00m

Ultimi guadagni dichiarati

Jun 30, 2024

Prossima data di guadagno

n/a

Utile per azione (EPS)	-0.88
Margine lordo	30.99%
Margine di profitto netto	-36.42%
Rapporto debito/patrimonio netto	40.4%

Come si è comportato HLS nel lungo periodo?

Vedi performance storica e confronto

HLS Panoramica delle azioni

Premi

Analisi del rischio

Healius Limited Concorrenti

ASX:ACL

AU$730.2m

ASX:IDX

AU$722.8m

ASX:CAJ

AU$415.6m

ASX:SHL

AU$13.0b

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Price target increased by 14% to AU$1.77

Affinity Equity Partners (Australia) Pty Limited entered into a binding agreement to acquire Lumus Imaging from Healius Limited (ASX:HLS) for enterprise value of AUD 965 million.

Price target increased by 8.4% to AU$1.68

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Healius Limited, Annual General Meeting, Nov 15, 2024

Price target increased by 7.5% to AU$1.51

Recent updates

Price target increased by 14% to AU$1.77

Affinity Equity Partners (Australia) Pty Limited entered into a binding agreement to acquire Lumus Imaging from Healius Limited (ASX:HLS) for enterprise value of AUD 965 million.

Price target increased by 8.4% to AU$1.68

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Healius Limited, Annual General Meeting, Nov 15, 2024

Price target increased by 7.5% to AU$1.51

Full year 2024 earnings: Revenues exceed analyst expectations

TPG Capital, PEP Reportedly Still Competing for Healius Lumus Imaging

Final Bids Reportedly Expected for Healius

Healius Limited Announces Step Down of Ravi Jeyaraj as Non-Executive Director, Effective 2 August 2024

Macquarie Unit Reportedly in Healius Race

Healius Limited to Report Fiscal Year 2024 Results on Aug 21, 2024

Sonic in the Running for Healius Imaging Business

Private Equity Reportedly Eyes Healius Diagnostic Imaging Unit

High number of new directors

Healius Limited to Report First Half, 2024 Results on Feb 27, 2024

Australian Clinical Labs Limited (ASX:ACL) cancelled the acquisition of Healius Limited (ASX:HLS) from Tanarra Capital Australia Pty Ltd, Perpetual Investment Management Ltd and others.

New minor risk - Shareholder dilution

Interim Non-Executive Independent Chair recently bought AU$81k worth of stock

High number of new directors

Healius Limited Appoints Ravi Jeyaraj as Director

Healius Limited Announces Chair Changes

Healius Limited Announces Chair Changes

Healius Limited has filed a Follow-on Equity Offering in the amount of AUD 187.32 million.

Healius Limited has filed a Follow-on Equity Offering in the amount of AUD 187.32 million.

Healius Limited, Annual General Meeting, Nov 01, 2023

Australian Clinical Labs Limited (ASX:ACL) canceled the acquisition of Healius Limited (ASX:HLS)

Healius Limited Appoints Michael Stanford as Director

Full year 2023 earnings: Revenues miss analyst expectations

Healius Limited to Report Fiscal Year 2023 Results on Aug 30, 2023

Consensus EPS estimates fall by 37%

Consensus EPS estimates fall by 37%

Healius Limited Appoints Jan Van Rooyen as Group Executive, Healius Pathology Effective 1 June 2023

Consensus EPS estimates increase by 34%

Consensus EPS estimates increase by 36%

Consensus EPS estimates increase by 22%

High number of new directors

Consensus EPS estimates increase by 18%

Is Healius Limited (ASX:HLS) Trading At A 50% Discount?

Independent Non Executive Chairman recently bought AU$103k worth of stock

First half 2023 earnings released: AU$0.045 loss per share (vs AU$0.40 profit in 1H 2022)

Consensus EPS estimates increase by 17%

Healius Limited Announces Resignation of Alison Stephenson as Company Secretary

Consensus EPS estimates fall by 21%

At AU$3.07, Is It Time To Put Healius Limited (ASX:HLS) On Your Watch List?

Healius Limited to Report First Half, 2023 Results on Feb 27, 2023

Consensus forecasts updated

Price target decreased to AU$3.23

Consensus EPS estimates fall by 13%

Nexus Hospitals entered into an agreement to acquire Montserrat Healthcare Pty Ltd from Healius Limited (ASX:HLS).

Here's Why Healius (ASX:HLS) Can Manage Its Debt Responsibly

Consensus EPS estimates fall by 27%

QIC Reportedly Set to Clinch Healius Day Hospital Unit for $140 Million Plus

MD, CEO & Director recently sold AU$660k worth of stock

Is Now An Opportune Moment To Examine Healius Limited (ASX:HLS)?

Brookfield Reportedly Drops Out of Race to Buy Healius

Independent Non Executive Director recently bought AU$86k worth of stock

Non Executive & Independent Director recently bought AU$70k worth of stock

MD, CEO & Director exercised options to buy AU$2.2m worth of stock.